Several other studies have reported that the number of PD-L1-positive CTCs from patients with NSCLC or different gastrointestinal tumors determined as PD increase significantly compared to that at baseline within 2–3 months after beginning of PD-1 blockade therapy [28,34]. Here, CD274 is linked to digestive system neoplasm.